Evidence mapPaperPMID 35431313Full record

ArticleThe American journal of case reports2022

Transient Complete Blindness Due to Metformin-Associated Lactic Acidosis (MALA) Reversed with Hemodialysis.

Libardo Rueda Prada, Lindsey Knopps, Igor Dumic, Christopher Barusya, Anand Subramanian, Antonios Charokopos, Adel S Zurob

Open access · hybridAbstract readCase Reports
In one paragraph

Article in The American journal of case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Libardo Rueda PradaDivision of Hospital Internal Medicine, Mayo Clinic Health System, Eau Claire, WI, USA.
Lindsey KnoppsFamily Medicine Residency, Mayo Clinic Health System, Eau Claire, WI, USA.
Igor DumicDivision of Hospital Internal Medicine, Mayo Clinic Health System, Eau Claire, WI, USA.ORCID 0000-0002-5312-8812
Christopher BarusyaDivision of Hospital Internal Medicine, Mayo Clinic Health System, Eau Claire, WI, USA.
Anand SubramanianDivision of Hospital Internal Medicine, Mayo Clinic Health System, Eau Claire, WI, USA.
Antonios CharokoposCollege of Medicine and Science, Mayo Clinic, Rochester, MN, USA.
Adel S ZurobCollege of Medicine and Science, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Metformin-associated lactic acidosis (MALA) is a relatively rare adverse effect of metformin therapy. It usually occurs in patients with metformin overdose or in those with underlying acute and/or chronic conditions resulting in impaired lactate metabolism. Among these, patients with acute kidney injury, heart failure, sepsis, and cirrhosis are the most vulnerable to MALA, even in the setting of appropriate therapy. The most common symptoms of MALA include nausea, vomiting, diarrhea, encephalopathy, hypothermia, respiratory failure, and hypotension. Blindness is a dramatic symptom that has been rarely reported with MALA. CASE REPORT We report a case of 78-year-old woman with history of type 2 diabetes mellitus with nephropathy for which she was treated with metformin and insulin. She developed nausea, non-bloody emesis, and watery diarrhea, which led to dehydration, anion gap metabolic acidosis due to hyperlactatemia, and acute kidney injury (AKI). She was hospitalized for i.v. hydration and further management when she suddenly developed blindness. The diagnostic work-up ruled out central causes and her symptoms resolved briefly after continuous renal replacement therapy (CRRT) was initiated, confirming the diagnosis of MALA. CONCLUSIONS By reporting this case, we wish to increase awareness about MALA symptoms, its diagnosis, and the importance of early recognition and initiation of treatment among clinicians involved in the care of patients with chronic kidney disease (CKD) who take metformin for diabetes mellitus. Although rare, this metformin adverse effect can present dramatically and can be distressing for both patient and treating team.

Indexed as

Acidosis, LacticAcute Kidney InjuryDiabetes Mellitus, Type 2MetforminAgedBlindnessDiarrheaFemaleHumansHypoglycemic AgentsMaleNauseaRenal DialysisHypoglycemic AgentsMetformin

Identifiers

PMID35431313
PMCPMC9026230
OpenAlexW4221107100

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.